More efficacious, safer drugs throughmechanobiology
By leveraging targets triggered by physical forces, we are able to equisitely target active disease areas and treat disease phenotypes rather than promiscuous biochemical signals.
40+ years of combined experience in Fibrosis Research and Biotech Start-up.
Annette Matthies, PhD
Annette brings 20 years of biotech experience in corporate strategy, business development, new product planning, and private and public fund raising. Broadening Annette’s Ph.D. expertise in immunology she has worked in the therapeutic areas of oncology and immuno-oncology (IO), inflammatory and autoimmune diseases, metabolic disease, and fibrosis.
Annette is currently the Chief Business Officer at Elicio Therapeutics. Prior to Elicio, Annette held positions of increasing responsibility in corporate development at eFFECTOR, Receptos (acquired by Celgene for $7.2B), Facet Biotech (acquired by Abbott for $450M), and Biogen Idec. Annette was a consult at L.E.K. consulting prior to her entrepeutrial roles in biotech.
Thomas Barker, PhD
Tom is an International Leader with 20+ years of Academic experience as a Principal Investigator (>$15M in grant funding) in the study of wound healing, mechanisms of fibrosis, and biotechnological & bioengineering solutions. He is the Founding Director of the UVA Fibrosis Inititative, boasting 30+ faculty studying fibrosis in multiple organ systems and previously served as co-Director of thePediatric Nanotechnology Center at GA Tech.
Tom has served as an expert witness and KOL in matters of fibrosis, fibrotic remodeling and drug targets to mitigate fibrotic outcomes. Tom co-founded SelSym Biotech in 2019, a start-up focused on “smart” nanotechnology for hemostasis applications in surgery and trauma.
John Nicosia, PhD
John is a bioengineer and business development professional, as well as a co-inventor of Vasarya’s anti-fibrosis technology. He is currently the Associate Director of Biolocity, a life sciences accelerator supporting early stage biomedical innovation at Georgia Tech and Emory University. Prior to Biolocity, John was a licensing associate for Emory’s Office of Technology Transfer, where he managed over 300 intellectual property assets and negotiated multiple licenses with biotech companies.